Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KDM1A | O60341 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CKS1B | P61024 | 3/20 | 0.38 |
| ▸ | SKP2 | Q13309 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6206302 | 0.81 | ABCB1 (0.48) | ABCB1LMNAKDM1AALDH1A1NPC1 | |
| SCHEMBL4639035 | 0.79 | GRM5 (0.34) | ALDH1A1 | |
| SCHEMBL6207550 | 0.78 | GRM5 (0.33) | ALDH1A1 | |
| SCHEMBL5746574 | 0.76 | KDM4E (0.33) | ALDH1A1 | |
| SCHEMBL5955395 | 0.76 | GRM5 (0.34) | — | |
| SCHEMBL6207910 | 0.75 | GRM5 (0.37) | ALDH1A1 | |
| SCHEMBL81282 | 0.74 | TSHR (0.41) | LMNAALDH1A1 | |
| SCHEMBL4814547 | 0.71 | TRPV1 (0.35) | LMNAALDH1A1NPC1RAB9A | |
| SCHEMBL6208843 | 0.71 | ABCB1 (0.48) | ABCB1LMNAKDM1AALDH1A1NPC1 | |
| SCHEMBL5250886 | 0.70 | GRM5 (0.34) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050272748-A1 | 2-Mercapto-substituted triazolopyrimidines, methods for the production thereof, the use of the same for controlling patogenic fungi, and agents containing said compounds | BASF AKTIENGESELLSCHAFT (DE) | 2005-12-08 | — | — | US | disclosed |
| EP-1575957-A1 | 2-MERCAPTO-SUBSTITUTED TRIAZOLOPYRIMIDINES, METHODS FOR THE PRODUCTION THEREOF, THE USE OF THE SAME FOR CONTROLLING PATHOGENIC FUNGI, AND AGENTS CONTAINING SAID COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004046149-A1 | 2-MERCAPTO-SUBSTITUTED TRIAZOLOPYRIMIDINES, METHODS FOR THE PRODUCTION THEREOF, THE USE OF THE SAME FOR CONTROLLING PATHOGENIC FUNGI, AND AGENTS CONTAINING SAID COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272748-A1 | 2-Mercapto-substituted triazolopyrimidines, methods for the production thereof, the use of the same for controlling patogenic fungi, and agents containing said compounds | NAT1, PNPO, CBR1 | ABCB1 2151/4885LMNA 2733/4885KDM1A 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.